Trial Outcomes & Findings for Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant (NCT NCT04933968)

Last Updated: 2024-06-06

Results Overview

A TEAE was defined as an adverse event (AE) with a start date and time on or after the first dose of study treatment. A serious AE (SAE) was an AE that met at least one of the following serious criteria: fatal, life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or other important medical event. TEAEs of special interest (AESI) included new/worsening graft versus host disease, graft failure or rejection, cytokine release syndrome, infusion related reactions, new/worsening pneumonitis, and progressive dyspnea. Treatment-related refers to the assessment of a relationship between study treatment and the event by the investigator.

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

17 participants

Primary outcome timeframe

Day 1 up to 12 months

Results posted on

2024-06-06

Participant Flow

Participants were enrolled at study centers in the United States and participated from March 2022 until January 2024.

Participants with respiratory tract infections and clinical manifestations caused by respiratory syncytial virus, influenza virus, human metapneumovirus, and/or parainfluenza virus following hematopoietic cell or solid organ transplants were enrolled. Participants were randomized in a double-blind manner to receive placebo or one of four dose levels of ALVR106, from Dose A (lower dose) to Dose D (higher dose). Due to early study termination, no participants were enrolled into Part B.

Participant milestones

Participant milestones
Measure	Part A: Placebo Participants were randomized to receive placebo, and were administered placebo as an intravenous (IV) infusion on Day 1. Participants returned to the clinic for assessments up to Day 14, and based on assessments could receive a second infusion of placebo on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 1: Dose A Participants were randomized to receive ALVR106, and were administered ALVR106 Dose A as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose A on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 2: Dose B Participants were randomized to receive ALVR106, and were administered ALVR106 Dose B as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose B on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 3: Dose C Participants were randomized to receive ALVR106, and were administered ALVR106 Dose C as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose C on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 4: Dose D Participants were randomized to receive ALVR106, and were administered ALVR106 Dose D as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose D on Day 14. Participants were followed for up to 12 months.
Overall Study STARTED	3	3	4	4	3
Overall Study COMPLETED	0	0	0	0	0
Overall Study NOT COMPLETED	3	3	4	4	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Part A: Placebo Participants were randomized to receive placebo, and were administered placebo as an intravenous (IV) infusion on Day 1. Participants returned to the clinic for assessments up to Day 14, and based on assessments could receive a second infusion of placebo on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 1: Dose A Participants were randomized to receive ALVR106, and were administered ALVR106 Dose A as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose A on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 2: Dose B Participants were randomized to receive ALVR106, and were administered ALVR106 Dose B as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose B on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 3: Dose C Participants were randomized to receive ALVR106, and were administered ALVR106 Dose C as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose C on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 4: Dose D Participants were randomized to receive ALVR106, and were administered ALVR106 Dose D as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose D on Day 14. Participants were followed for up to 12 months.
Overall Study Adverse Event	0	0	1	1	0
Overall Study Lost to Follow-up	1	0	1	0	0
Overall Study Randomized not treated	1	0	0	0	0
Overall Study Sponsor terminated study	0	0	0	1	2
Overall Study Other	0	0	0	1	0
Overall Study Missing	1	3	2	1	1

Baseline Characteristics

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part A: Placebo n=2 Participants Participants were randomized to receive placebo, and were administered placebo as an IV infusion on Day 1. Participants returned to the clinic for assessments up to Day 14, and based on assessments could receive a second infusion of placebo on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 1: Dose A n=3 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose A as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose A on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 2: Dose B n=4 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose B as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose B on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 3: Dose C n=4 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose C as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose C on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 4: Dose D n=3 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose D as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose D on Day 14. Participants were followed for up to 12 months.	Total n=16 Participants Total of all reporting groups
Age, Customized ≤ 18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Age, Customized 19 - 70 years	2 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	4 Participants n=4 Participants	3 Participants n=21 Participants	16 Participants n=10 Participants
Age, Customized ≥ 71 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	7 Participants n=10 Participants
Sex: Female, Male Male	2 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	3 Participants n=4 Participants	2 Participants n=21 Participants	9 Participants n=10 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	2 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	4 Participants n=4 Participants	2 Participants n=21 Participants	15 Participants n=10 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Race/Ethnicity, Customized White	1 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	4 Participants n=4 Participants	3 Participants n=21 Participants	15 Participants n=10 Participants
Race/Ethnicity, Customized Not reported	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants

PRIMARY outcome

Timeframe: Day 1 up to 12 months

Population: The safety population included all randomized participants who received any amount of ALVR106 or placebo.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=2 Participants Participants were randomized to receive placebo, and were administered placebo as an IV infusion on Day 1. Participants returned to the clinic for assessments up to Day 14, and based on assessments could receive a second infusion of placebo on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 1: Dose A n=3 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose A as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose A on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 2: Dose B n=4 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose B as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose B on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 3: Dose C n=4 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose C as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose C on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 4: Dose D n=3 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose D as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose D on Day 14. Participants were followed for up to 12 months.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Part A) Any AESI	1 Participants	1 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Part A) Any treatment-related AESI	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Part A) Any SAE	0 Participants	2 Participants	3 Participants	3 Participants	1 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Part A) Any treatment-related SAE	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Part A) Any TEAE leading to study treatment discontinuation	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Part A) Any TEAE leading to death	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Part A) Any TEAE	2 Participants	3 Participants	4 Participants	4 Participants	3 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Part A) Any treatment-related TEAE	2 Participants	1 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Baseline and Day 28 (Part B)

Population: No participants were enrolled into Part B due to the early termination of the study.

Change from Baseline in viral load as measured by quantitative PCR of nasal swab

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Day 1 up to 12 months

Population: All randomized participants who received ALVR106 in Part A.

The RP2D was to be determined after the maximum tolerated dose was reached in Part A.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=14 Participants Participants were randomized to receive placebo, and were administered placebo as an IV infusion on Day 1. Participants returned to the clinic for assessments up to Day 14, and based on assessments could receive a second infusion of placebo on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 1: Dose A Participants were randomized to receive ALVR106, and were administered ALVR106 Dose A as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose A on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 2: Dose B Participants were randomized to receive ALVR106, and were administered ALVR106 Dose B as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose B on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 3: Dose C Participants were randomized to receive ALVR106, and were administered ALVR106 Dose C as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose C on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 4: Dose D Participants were randomized to receive ALVR106, and were administered ALVR106 Dose D as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose D on Day 14. Participants were followed for up to 12 months.
Identify the Recommended Phase 2 Dose (RP2D) (Part A)	NA x 10^5 cells/kg The MTD and RP2D could not be determined due to too few dose-limiting toxicities during the study prior to early study termination.	—	—	—	—

SECONDARY outcome

Timeframe: Baseline and Day 28

Population: The modified intent-to-treat population included all randomized participants who received any amount of ALVR106 or placebo and had confirmed virologic infection of interest at baseline (detectable viral load). Participants with baseline and Day 28 available data are included.

Viral load was measured by quantitative polymerase chain reaction (PCR) of nasal swab specimens. The cycle threshold value categorizes the concentration of viral genetic material in a participant's swab specimen, and the cycle threshold value represents the number of PCR cycles required to amplify the viral genetic material (as measured by fluorescence) to a detectable level that is distinguishable from baseline fluorescence, providing an estimate of viral load. Lower cycle threshold values indicate higher viral load and high values indicate lower viral load. A positive change from baseline indicates a decrease in the viral load. The baseline measurement was from a pre-dose nasal swab.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=1 Participants Participants were randomized to receive placebo, and were administered placebo as an IV infusion on Day 1. Participants returned to the clinic for assessments up to Day 14, and based on assessments could receive a second infusion of placebo on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 1: Dose A n=1 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose A as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose A on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 2: Dose B n=4 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose B as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose B on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 3: Dose C n=4 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose C as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose C on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 4: Dose D n=3 Participants Participants were randomized to receive ALVR106, and were administered ALVR106 Dose D as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose D on Day 14. Participants were followed for up to 12 months.
Change in Viral Load Cycle Threshold From Baseline to Day 28 (Part A)	8.60 cycles Standard Deviation NA Standard deviation could not be determined as 1 participant was analyzed.	4.40 cycles Standard Deviation NA Standard deviation could not be determined as 1 participant was analyzed.	8.43 cycles Standard Deviation 6.118	5.78 cycles Standard Deviation 4.696	7.47 cycles Standard Deviation 7.551

SECONDARY outcome

Timeframe: Day 1 up to 12 months

Population: No participants were enrolled into Part B due to the early termination of the study.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Day 1 and Month 6

Population: No participants were enrolled into Part B due to the early termination of the study.

Outcome measures

Outcome data not reported

Adverse Events

Part A: Placebo

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Part A ALVR106 Cohort 1: Dose A

Serious events: 2 serious events

Other events: 3 other events

Deaths: 0 deaths

Part A ALVR106 Cohort 2: Dose B

Serious events: 3 serious events

Other events: 4 other events

Deaths: 2 deaths

Part A ALVR106 Cohort 3: Dose C

Serious events: 3 serious events

Other events: 4 other events

Deaths: 2 deaths

Part A ALVR106 Cohort 4: Dose D

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Part A: Placebo n=2 participants at risk Participants were randomized to receive placebo, and were administered placebo as an IV infusion on Day 1. Participants returned to the clinic for assessments up to Day 14, and based on assessments could receive a second infusion of placebo on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 1: Dose A n=3 participants at risk Participants were randomized to receive ALVR106, and were administered ALVR106 Dose A as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose A on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 2: Dose B n=4 participants at risk Participants were randomized to receive ALVR106, and were administered ALVR106 Dose B as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose B on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 3: Dose C n=4 participants at risk Participants were randomized to receive ALVR106, and were administered ALVR106 Dose C as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose C on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 4: Dose D n=3 participants at risk Participants were randomized to receive ALVR106, and were administered ALVR106 Dose D as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose D on Day 14. Participants were followed for up to 12 months.
Infections and infestations Pneumonia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations COVID-19	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Oesophageal candidiasis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Odynophagia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia recurrent	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	50.0% 2/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
General disorders Non-cardiac chest pain	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Renal and urinary disorders Acute kidney injury	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Bronchial hyperreactivity	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Sepsis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Liver function test increased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Viral haemorrhagic cystitis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Septic shock	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
General disorders Pyrexia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Ascites	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Hypervolaemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Psychiatric disorders Mental status changes	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Endocrine disorders Thyroiditis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Cardiac disorders Cardiomyopathy	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.

Other adverse events

Other adverse events
Measure	Part A: Placebo n=2 participants at risk Participants were randomized to receive placebo, and were administered placebo as an IV infusion on Day 1. Participants returned to the clinic for assessments up to Day 14, and based on assessments could receive a second infusion of placebo on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 1: Dose A n=3 participants at risk Participants were randomized to receive ALVR106, and were administered ALVR106 Dose A as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose A on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 2: Dose B n=4 participants at risk Participants were randomized to receive ALVR106, and were administered ALVR106 Dose B as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose B on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 3: Dose C n=4 participants at risk Participants were randomized to receive ALVR106, and were administered ALVR106 Dose C as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose C on Day 14. Participants were followed for up to 12 months.	Part A ALVR106 Cohort 4: Dose D n=3 participants at risk Participants were randomized to receive ALVR106, and were administered ALVR106 Dose D as an IV infusion on Day 1. Participants returned to the clinical site for assessments up to Day 14, and based on assessments could receive a second infusion of ALVR106 Dose D on Day 14. Participants were followed for up to 12 months.
Infections and infestations COVID-19	50.0% 1/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	75.0% 3/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Sepsis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Oral candidiasis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	66.7% 2/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Urinary tract infection	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations BK virus infection	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations COVID-19 pneumonia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Clostridium difficile colitis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Enterococcal bacteraemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Influenza	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Klebsiella bacteraemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Oesophageal candidiasis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Oral herpes	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Otitis media	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Parainfluenzae virus infection	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Pneumonia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Rhinovirus infection	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Urinary tract infection enterococcal	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Infections and infestations Vulvovaginal candidiasis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Constipation	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Diarrhoea	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Nausea	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Vomiting	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Ascites	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Hyperaesthesia teeth	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Gastrointestinal disorders Odynophagia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
General disorders Pyrexia	50.0% 1/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
General disorders Fatigue	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
General disorders Non-cardiac chest pain	50.0% 1/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
General disorders Chills	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
General disorders Influenza like illness	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
General disorders Oedema peripheral	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations White blood cell count decreased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	50.0% 2/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Neutrophil count decreased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	50.0% 2/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Platelet count decreased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Alanine aminotransferase increased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Aspartate aminotransferase increased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Blood bilirubin increased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Blood creatine phosphokinase increased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Blood creatinine increased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Blood lactate dehydrogenase increased	50.0% 1/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Transfer factor reduced	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Investigations Vitamin D decreased	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Hypervolaemia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Metabolism and nutrition disorders Vitamin B12 deficiency	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	50.0% 2/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Musculoskeletal and connective tissue disorders Osteopenia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Musculoskeletal and connective tissue disorders Myositis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Nasal congestion	50.0% 1/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Bronchospasm	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Hypercapnia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Respiratory, thoracic and mediastinal disorders Sinus pain	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Skin and subcutaneous tissue disorders Decubitus ulcer	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Skin and subcutaneous tissue disorders Skin hyperpigmentation	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Blood and lymphatic system disorders Eosinophilia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Blood and lymphatic system disorders Pancytopenia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Ear and labyrinth disorders Ear pain	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Ear and labyrinth disorders Ear discomfort	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Immune system disorders Acute graft versus host disease in skin	50.0% 1/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Immune system disorders Chronic graft versus host disease in lung	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Immune system disorders Chronic graft versus host disease oral	50.0% 1/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Post transplant lymphoproliferative disorder	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Nervous system disorders Dizziness	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Nervous system disorders Encephalopathy	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Nervous system disorders Muscle tension dysphonia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Nervous system disorders Paraesthesia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Vascular disorders Deep vein thrombosis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Vascular disorders Hot flush	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Vascular disorders Superficial vein thrombosis	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Cardiac disorders Sinus tachycardia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Endocrine disorders Hypogonadism	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Psychiatric disorders Depression	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Psychiatric disorders Insomnia	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Renal and urinary disorders Polyuria	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Congenital, familial and genetic disorders Chimerism	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Eye disorders Dry eye	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	25.0% 1/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Hepatobiliary disorders Biliary obstruction	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.
Hepatobiliary disorders Portal hypertension	0.00% 0/2 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	0.00% 0/4 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.	33.3% 1/3 • Day 1 up to 12 months. AEs are presented for the safety population for Part A which included all randomized participants who received any amount of ALVR106 or placebo. Due to early study termination, no participants were enrolled into Part B and therefore Part B is not included in the AE data.

Additional Information

Senior Vice President

AlloVir, Inc.

Phone: +1 617-433-2605

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place